Recent trials such as the Phase III CASSIOPEIA trial (NCT02541383) have demonstrated how a negative measurable residual disease (MRD) response can be achieved in a majority of patients in newly diagnosed multiple myeloma. However, a number of remaining patients require extra treatment and Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, discusses the latest advances in immunotherapy for this group of patients. CAR-Ts, B-cell maturation antigens (BCMA), as well as bispecific antibodies such as elranatamab and teclistamab represent a novel class of treatments for patients who fail existing therapies. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda; Advisory Board: Amgen, BMS, Celgene, Janssen, Karyopharm, Takeda.